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Abstract 
Here we report a series of close analogues of our recently published scaffold-based 
tripeptidomimetic CXCR4 antagonists, containing positively charged guanidino groups in R1 
and R2, and an aromatic group in R3. While contraction/elongation of the guanidine carrying 
side chains (R1 and R2) resulted in loss of activity, introduction of bromine in position 1 on 
the naphth-2-ylmethyl moiety (R3) resulted in an EC50 of 61 µM (mixture of 
diastereoisomers) against wild-type CXCR4; thus, the antagonistic activity of these 
tripeptidomimetics seems to be amenable to optimization of the aromatic moiety. Moreover, 
for analogues carrying a naphth-2-ylmethyl substituent, we observed that a Pictet-Spengler 
































The G protein coupled CXC chemokine receptor 4 (CXCR4) and its only known endogenous 
ligand, the 68-residue CXC chemokine ligand 12 (CXCL12), are involved in development 
and chemotaxis of leucocytes and lymphocytes,1-3 as well as in embryogenesis by 
participating in vascularization of the gastrointestinal tract,4 neural development5 and 
haematopoiesis.6 Since the CXCR4/CXCL12 axis also has been shown to have a pathological 
role in HIV, cancer and rheumatoid arthritis7 CXCR4 is an attractive drug target, and several 
small-molecule CXCR4 antagonists have been described in the literature.7-9 Plerixafor, the 
only small-molecule CXCR4 antagonist that has been approved so far, is used for 
mobilization of hematopoietic stem cells prior to autologous bone marrow transplantation in 
patients with Hodgkin disease, non-Hodgkin’s lymphoma and multiple myeloma.10, 11 Other 
small molecule CXCR4 antagonists are undergoing clinical trials; among them is the orally 
available AMD11070, which is investigated for its efficacy against HIV infection.12  
 
In addition to the small-molecule antagonists, a large number of potent peptide antagonists for 
CXCR4 have been identified.13-17 From a drug discovery perspective, a series of head-to-tail 
cyclized pentapeptides originally reported by Fujii and co-workers,18 i.e. cyclo(-L/D-Arg1-
Arg2-2-Nal3-Gly4-D-Tyr5-) (1 and 2, Figure 1A) represents a particularly attractive starting 
point. Extensive SAR studies of 1 and 219 indicate that the main activity of the 
cyclopentapeptide CXCR4 antagonists resides in the L/D-Arg1-Arg2-2-Nal3 tripeptide 
fragment, which again suggests that tripeptidomimetic compounds based on this motif are 
interesting as small-molecule CXCR4 antagonists. We have recently reported a novel class of 
Arg-Arg-2-Nal tripeptidomimetic CXCR4 antagonists,20 which were based on the 
synthetically accessible bicyclic scaffold A (3,6,8-trisubstituted 4,7-dioxo-1-thia-5,8-diaza-
bicyclo[4.4.0]decane, Figure 1B).21 Our prototype compounds 3a and 3b (Figure 1C) were 
shown to have EC50 values of 64 µM and 80 µM, respectively,20 and in the current study we 
have investigated the immediate SAR of these hit compounds by synthesizing close analogues 




   
Figure 1. Structures of (A) the cyclic pentapeptide CXCR4 antagonists 1 and 2 reported by Fujii et al.18; (B) the 
bicyclic scaffold A employed for our tripeptidomimetic CXCR4 antagonists; (C) the active tripeptidomimetic hit 
compounds 3a and 3b20; (D) the inactive analogues 4 and 5 containing an amide bond in the R1-side chain.20 
 
2. Results and discussion 
2.1. Design and SAR – Our prototype hit compounds 3a and 3b contain Arg-side chains in 
R1 and R2 and a 2-naphthyl group with an ethylene spacer in R3 (Figure 1C). Analogues with 
an amide group in the R1 side chain can be conveniently synthesized by employing 
appropriately protected Cys residues as building blocks; however, since we previously found 
4 and 5 (Figure 1D) to be inactive,20 this strategy was abandoned. Instead, our synthetic 
strategy for the target compounds 6–12 in the current work (Table 1) was based on a racemic 
building block for introduction of the R1-side chain (see Chemistry below), giving both the 
(3R,6S,9aS) and the (3S,6S,9aR) diastereoisomer (a and b, respectively). The antagonistic 


























































































First, compounds with two (6a and 6b) and four carbon atoms (7a and 7b) in the R1 side 
chain were synthesized in order to determine the importance of side chain length. However, 
none of these four analogues showed biological activity, demonstrating that 
contraction/elongation of the R1 side chain is unfavourable.  
 
The length of the R2 side chain was then increased by one carbon atom (8a and 8b), but this 
elongation resulted in loss of biologic activity. Compounds 9a and 9b, where a shorter R1 side 
chain was incorporated to compensate the longer R2 side chain, were also included; however, 
these compounds were similarly inactive.   
 
Next, the R3 side chain spacer was shortened to one carbon atom (10a/10b and 11a/11b). 
Neither diastereoisomers of 10 or 11 were separable by preparative RP-HPLC, thus both were 
tested as the respective diastereomeric mixtures. Compound 10a,b did not show biological 
activity; however, the C-1 bromine-substituted analogue 11a,b had an EC50 value of 61 µM. 
The bromine was introduced to avoid a suspected Pictet-Spengler type side reaction in the 
synthesis of these analogues (see Chemistry below), and since this substitution simultaneously 
affects the steric, electronic, and hydrophobic properties of the aromatic moiety, it is difficult 
to isolate the exact cause of the difference in activity between 10 and 11. Still, the fact that 
11a,b is equipotent with 3b indicates that there is room for further optimization of the R3-side 
chain. 
 
Finally, we included 12a and 12b, which are the 1-substituted isomers of 10a and 10b. 





Table 1. Structures of compounds 3 and 6-12 and antagonistic potency on human CXCR4. 
 
 
Compd m (R1) 
n 
(R2) R
3 log EC50 ± SEM EC50 (µM) 
3aa 
3ba 3 3  
−4.20 ± 0.12 



























10a, 10bb 3 3  > −4 >100 
11a, 11bb 3 3 
 
−4.21 ± 0.02 61 
12a, 12bb 3 3 
 
> −4 >100 
a Known compounds; biological data taken from Zachariassen et al.20; b Inseparable diastereoisomers, 
tested as the diastereomeric mixture. 
 
2.2. Chemistry – All target compounds in this study are based on the 6,6-fused bicyclic ring 
system of scaffold A (Scheme 1), which can be prepared from linear precursor C. Synthesis 
of the linear precursors requires the coupling of three building blocks (D – F) bearing each of 
the side chains. Treatment of the linear precursor C with a TFA cocktail liberates the 
aldehyde from the dimethyl acetal, which is then attacked by the amide nitrogen to form the 
N-acyliminium ion B. Finally, nucleophilic attack by the thiol results in the formation of the 























Scheme 1. Retrosynthetic strategy for synthesis of the bicylic scaffold A. 
 
For the synthesis of 6a,b – 9a,b the required secondary amine 14 carrying the R3 side chain 
was prepared by alkylation of primary amine 13 using bromoacetaldehyde dimethyl acetal in 
DMF (Scheme 2). 
 
 
Scheme 2. Synthesis of 14. Reagents and conditions: (a) BrCH2CH(OMe)2, K2CO3, DMF, 80 °C (52%). 
 
Towards the synthesis of bicycles 10a,b, 11a,b and 12a,b secondary amines 18-20 were 
prepared from the appropriate aldehydes 15-17 by reductive amination through reaction with 
2,2-dimethoxyethylamine followed by reduction with NaBH4 (Scheme 3). 
 
Scheme 3. Reductive aminations. Reagents and conditions: (b) i) NH2CH2CH(OMe)2, 90-100 °C; ii) NaBH4, rt 
(44-87%). 
 
The different building blocks bearing the R1 side chain were prepared starting from Boc-
protected lactams 21-23 (Scheme 4). α-Methylenation through release of trifluoroacetate23 
gave Michael acceptors 24-26, which after reaction with Ph3CSH using Et3N as base gave the 
racemic Michael products 27-29 in good yields. Subsequent hydrolysis with LiOH gave the 








































15 Ar = Naphth-2-yl
16 Ar = 1-Bromo-naphth-2-yl
17 Ar = Naphth-1-yl
a
18 Ar = Naphth-2-yl
19 Ar = 1-Bromo-naphth-2-yl
20 Ar = Naphth-1-yl
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Scheme 4. Synthesis of carboxylic acid building blocks. Reagents and conditions: (a) 1. CF3CO2CH2CF3, 
LiHMDS, 20 – 30 minutes, rt; 2. (CH2O)n, toluene, 80 °C, 2 h (41 – 57% over 2 steps); (b) Ph3CSH, Et3N, 
CH2Cl2, rt, 23 – 44 h (39 – 59%); (c) 1 M aq LiOH, THF, rt, 1 – 3 h (64 – 81%). 
 
The linear precursor were prepared by coupling the secondary amines 14, 18, 19 and 20 with 
Fmoc-Arg(Pbf)-OH, Fmoc-Orn(Boc)-OH or Fmoc-Lys(Boc)-OH to give coupling products 
33-38 (Scheme 5). Next, the Fmoc-group was removed using diethylamine and the free 
amines were coupled with the racemic carboxylic acids 30, 31 or 32 to yield the linear 
precursors 39-45 as inseparable diastereoisomeric mixtures. Further, treatment with a mixture 
of TFA, thioanisole and water lead to global deprotection and formation of the bicyclic ring 
system.24 Finally, the R1 side chain amines (also R2 for 40 and 41) were guanidinylated to 
give the final crude products.  
 
Scheme 5. Synthesis of bicycles. Reagents and conditions: (a) Fmoc-Arg(Pbf)-OH, Fmoc-Orn(Boc)-OH or 
Fmoc-Lys(Boc)-OH, HATU, DIPEA, CH2Cl2 or DMF, rt (70-85%); (b) Et2NH, CH2Cl2, rt; (c) HATU or HBTU, 
DIPEA, CH2Cl2, rt (17%-75% over two steps); (d) TFA/thioanisole/H2O, rt; (e) 1H-pyrazole-1-carboxamidene x 
HCl, DIPEA, DMF (6-31% over 2 steps). 
 
All final compounds were purified by RP-HPLC, however the diastereoisomers of 10, 11 and 
12 proved for all practical purposes to be inseparable. For 6-9, the two diastereoisomers that 
were formed were separable by RP-HPLC and analysis of the purified compounds by NMR 
spectroscopy clearly showed that they were single diastereoisomers. As the stereochemistry at 
C6 was fixed through incorporation of appropriately protected (S)-Arg, (S)-Orn or (S)-Lys 
(Scheme 5), the configuration at C3 and C9a (see Tables 1 and S1) could be determined by 




21 n = 1
22 n = 2












24 n = 1
25 n = 2
26 n = 3
27 n = 1
28 n = 2
29 n = 3
30 n = 1
31 n = 2

































isolated as single diastereoisomers, strong cross-peaks between H3 and H9a were observed.  
Further, for the diastereoisomer that displayed the longest retention time of the pairs, strong 
cross-peaks between H9a and Hb/Hγ of the R2 side-chain were always observed (see Table S1 
for further details). These findings indicate that all compounds have the same configurations 
as reported for hit compounds 3a and 3b,20 and that the (3R,6S,9aS) diastereoisomer (6a-9a) 
always eluted first and the (3S,6S,9aR) diastereoisomer (6b-9b) always eluted last from the 
C18-column for the separable diastereoisomeric pairs. 
 
The bromine of 11a,b was originally introduced as a protecting group as we observed a side 
reaction in an attempted synthesis of bicycle 47 (Scheme 6). 
 
Scheme 6. Attempted synthesis of 47. 
 
In our attempted synthesis of compound 47 (see SI for experimental details), compound 48 
was instead the only product that could be isolated in pure form. Inspection of the 1H NMR 
spectrum of the isolated compound quickly revealed that it was not the desired product as the 
signals in the aromatic region integrated to 6 protons instead of 7. The combined information 
obtained from the 2D 1H-13C HMBC and HSQC spectra revealed the presence of four 
quaternary carbon signals in the aromatic region. The structure of 48 was elucidated by 
extensive use of 2D NMR. Thus, it would seem that after formation of the N-acyliminium ion 
B (Scheme 1), the cyclization can take two different paths; either the thiol attacks the carbon 
atom in the double bond to yield the desired cyclization product,21 or an aromatic substitution 
reaction, i.e. a Pictet Spengler-type reaction, takes place.26 The 2D 1H-1H ROESY spectrum 
of 48 revealed no ROE between the bridge-head proton and the R2 side chain, thus the 
nucleophilic attack on the acyliminium ion has occurred from the same side as the R2 side 
chain. 
In order to avoid the Pictet-Spengler product, bromine was introduced in the 1-position of the 
naphthalene group by starting with 1-bromo-2-naphthaldehyde (16) when preparing the 

































be removed from the cyclized product by treatment with hydrogen gas in the presence of 
Pd/C.27 The protection of the naphthalene proved however to be unnecessary, as the 
cyclization pathway was found to be highly dependent on the nature of the R1 side chain (see 
SI for details) and cyclization of linear precursors 43, which contains a naphth-2-ylmethyl R3 
side chain and a three carbon spacer in the R1 side chain, gave the desired bicycles as the 
major products (Scheme 7). Similar chemoselectivity was observed when the R1 side chain 
was omitted (see SI for details), indicating that the electron withdrawing ammonium 
substituent (or Boc-protected amine if Boc deprotection is slower than cyclization) of the N-
acyliminium ion formed from 46 (Scheme 6) decreases the nucleophilicity of the thiol. 
 
 
Scheme 7. Successful cyclization. Reagents and conditions: (a) TFA/thioanisole/H2O (90:5:5) 
 
3. Conclusions 
In summary, we have investigated close analogues of our earlier reported hit compounds 
based on a tripeptidomimetic scaffold for CXCR4 antagonists by varying the spacer length for 
the three side chains. Our results suggests that a three-carbon spacer is optimal for both of the 
guanidine carrying side chains, while the aromatic group in the R3 position can still be 
optimized. Interestingly, we found that a side reaction of analogues carrying a naphth-2-
ylmethyl substituent through a Pictet-Spengler like cyclization reaction was dependent on the 
nature of the R1 substituent. Finally, introducing bromine in position 1 on the naphtha-2-
ylmethyl moiety gave a mixture of inseparable diastereoisomers with an EC50 of 61 µM 
against wild-type CXCR4, thus the antagonistic activity of these tripeptidomimetics seems to 
be amenable to changes on the aromatic moiety. 
 
4. Experimental 
4.1. Chemistry - All reagents and starting materials were purchased from Sigma-Aldrich and 
used as delivered unless otherwise stated. Boc-protected lactam 22 was prepared following a 
literature procedure.28 Anhydrous toluene and THF were obtained from an anhydrous solvent 




































Bergen. CH2Cl2 was dried over molecular sieves. For analysis by thin layer chromatography, 
aluminium sheets coated with Merck KGaA silica gel (60 F254) were used. The TLC plates 
were visualized using either ultraviolet light or by immersion in a solution of 2% ninhydrin in 
ethanol supplemented with 10 drops of concentrated sulphuric acid pr 100 mL solution, 
followed by heating. Purification by flash column chromatography was performed on Merck 
KGaA Kieselgel (230 – 400 mesh). All final compounds were purified by semi-preparative 
RP-HPLC eluting with mixtures of acetonitrile and H2O (both containing 0.1% TFA). 
Fractions of equal purity were pooled and lyophilized. All tested compounds were analysed 
by RP-HPLC and found to be of > 95% purity (sum of isomers for inseparable 
diastereoisomers).  
 
4.1.1. 2,2-Dimethoxy-N-(2-(naphthalen-2-yl)ethyl)ethan-1-amine (14) 
To a stirring solution of 2-(naphthalen-2-yl)ethan-1-amine (0.39 g, 2.28 mmol) in anhydrous 
DMF (10 mL), K2CO3 (0.32 g, 2.34 mmol) and bromoacetaldehyde dimethyl acetal (0.38 mL, 
3.33 mmol) were added and the resulting suspension was then heated at 80 °C for 26 h. The 
reaction was quenched with H2O (20 mL), extracted with EtOAc (3 x 20 mL), washed with 
brine (20 mL) and dried over MgSO4. The solvent was removed under reduced pressure to 
give the crude product as an orange oil (475 mg). The crude product was purified by flash 
column chromatography on silica gel (EtOAc/MeOH 9:1) to give the title compound as a 
yellow oil (307 mg, 52%). Rf (EtOAc/MeOH 9:1) = 0.15; 1H NMR (400 MHz, CDCl3) δ = 
7.82-7.75 (m, 3H), 7.65 (s, 1H), 7.48 – 7.40 (m, 2H), 7.34 (dd, J = 8.4, 1.7, 1H), 4.48 (t, J = 
5.5, 1H), 3.35 (s, 6H), 2.99 (s, 4H), 2.80 (d, J = 5.5, 2H), 2.17 (bs, 1H); 13C NMR (101 MHz, 
CDCl3): δ = 137.3, 133.7, 132.2, 128.2, 127.7, 127.5, 127.3, 127.1, 126.1, 125.4, 103.8, 54.2, 
51.2, 51.1, 36.5; HRMS (ESI): m/z [M + H]+ calcd for C16H22NO2: 260.1651; found: 
260.1651. 
 
4.1.2. 2,2-Dimethoxy-N-(naphthalen-2-ylmethyl)ethan-1-amine (18) 
A mixture of 2-naphthaldehyde (845 mg, 5.4 mmol) and aminoacetaldehyde dimethyl acetal 
(0.6 mL, 5.5 mmol) was heated at 100 °C for 20 min and then cooled to room temperature. 
The reaction mixture was then diluted with EtOH (4 mL) and NaBH4 (207 mg, 5.5 mmol) was 
added in small portions to the stirring mixture. The reaction mixture was stirred for 22 h 
before the EtOH was removed and the residue was portioned between H2O (10 mL) and 
EtOAc (40 mL). The organic phase was washed with H2O (2 x 10 mL), dried over MgSO4, 
filtered and concentrated to give the crude product as yellow oil (1.262 g). Purification by 
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flash column chromatography on silica gel (EtOAc/MeOH 92.5:7.5) gave the title compound 
as yellow oil (893 mg, 67%). Rf (EtOAc/MeOH 92.5:7.5) = 0.31; 1H NMR (400 MHz, 
CDCl3): δ = 7.83 – 7.74 (m, 4H), 7.47 – 7.40 (m, 3H), 4.50 (t, J = 5.5, 1H), 3.97 (s, 2H), 3.36 
(s, 6H), 2.79 (d, J = 5.5, 2H); 13C NMR (100 MHz, CDCl3): δ = 137.6, 133.5, 132.7, 128.1, 
127.7, 127.7, 126.6, 126.5, 126.0, 125.6, 104.0, 54.0, 54.0, 50.6; HRMS (ESI): m/z [M + H]+ 
calcd for C15H20NO2: 246.1494; found: 246.1497. 
 
4.1.3. N-((1-Bromonaphthalen-2-yl)methyl)-2,2-dimethoxyethan-1-amine (19) 
The title compound was prepared from 1-bromo-2-naphthaldehyde (202 mg, 0.9 mmol) 
following the protocol described for 18 above. The crude product (yellowish oil, 243 mg) was 
purified by flash column chromatography on silica gel (EtOAc) to give the title compound as 
yellowish oil (124 mg, 44%). Rf (EtOAc) = 0.27; 1H NMR (400 MHz, CDCl3) δ = 8.33 (dd, 
8.5, 1H), 7.85 – 7.76 (m, 2H), 7.62 – 7.56 (m, 1H), 7.55 – 7.48 (m, 2H), 4.52 (t, J = 5.5, 1H), 
4.14 (s, 2H), 3.37 (s, 6H), 2.80 (d, J = 5.5, 2H), 1.80 (bs, 1H); 13C NMR (100 MHz, CDCl3) δ 
= 137.4, 134.0, 132.6, 128.2, 127.8, 127.7, 127.5, 127.3, 126.4, 124.0, 103.9, 54.7, 54.0, 50.4; 
HRMS (ESI): m/z [M + H]+ calcd for C15H19O2N79Br: 324.0599; found: 324.0599; HRMS 
(ESI): m/z [M + Na]+ calcd for C15H18O2N79BrNa: 346.0419; found: 346.0415.  
 
4.1.4. 2,2-Dimethoxy-N-(naphthalene-1-ylmethyl)ethanamine (20) 
The title compound was prepared from 1-naphthaldehyde (0.55 mL, 4.0 mmol) following the 
protocol described for 18 above, except that the temperature in the first step was 90 °C. The 
crude product (red/brown oil, 855 mg, 87%) was used without further purification. Rf 
(EtOAc) = 0.23; 1H NMR (400 MHz, CDCl3) δ = 8.12 (d, J = 8.3, 1H), 7.89 – 7.70 (m, 2H), 
7.55 – 7.36 (m, 4H), 4.51 (t, J = 5.5, 1H), 4.25 (s, 2H), 3.35 (s, 6H), 2.86 (d, J = 5.5, 2H), 
1.62 (s, 1H); 13C NMR (101 MHz, CDCl3) δ = 135.9, 134.1, 132.0, 128.9, 128.0, 126.3, 
126.2, 125.8, 125.6, 123.8, 104.1, 54.1, 51.7, 51.2; HRMS (ESI): m/z [M + H]+ calcd for 
C15H20NO2: 246.1489; found: 246.1493. 
 
4.1.5. tert-Butyl 3-methylene-2-oxopyrrolidene-1-carboxylate (24) 
A solution of 21 (0.27 mL, 1.58 mmol) in dry THF (7 mL) was transferred to a stirring 
solution of LiHMDS (1 M in THF, 3.24 mL, 3.24 mmol) at 0 °C via cannulation. The reaction 
mixture was allowed to warm up to room temperature over 38 minutes before 2,2,2-
trifluoroethyl trifluoroacetate (0.40 mL, 2.99 mmol) was added. Stirring was continued for 
additional 20 minutes at room temperature before the reaction was quenched with saturated 
	 13	
NH4Cl (25 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated to yield a dark yellow oil (305 mg). The oil was 
dissolved in dry toluene (24 mL) and paraformaldehyde (1.18 g, 40.3 mmol) and K2CO3 (472 
mg, 3.41 mmol) were added to the solution. The reaction mixture was heated at 108 °C for 2 h 
before quenched with saturated NH4Cl (40 mL) and extracted with EtOAc (3 x 30 mL), dried 
over MgSO4, filtered and concentrated to give the crude product as yellow oil (312 mg). 
Purification by flash column chromatography on silica gel (hexanes/EtOAc 2:1) gave the title 
compound (178 mg, 57%). Rf (hexanes/EtOAc 2:1) = 0.25; 1H NMR (400 MHz, CDCl3): δ = 
6.19 (t, J = 2.8, 1H), 5.48 (t, J = 2.5, 1H), 3.73 (t, J = 7.3, 2H), 2.78 – 2.72 (m, 2H), 1.55 (s, 
9H); 13C NMR (101 MHz, CDCl3): δ = 166.6, 151.0, 139.2, 120.0, 83.2, 43.1, 28.2, 23.3; 
HRMS (ESI): m/z [M + Na]+ calcd for C10H15NO3Na: 220.0950; found: 220.0949; m/z [2M + 
Na]2+ calcd C20H30N2O6Na: 417.2002; found: 417.2025. 
 
4.1.6. tert-Butyl 3-methylene-2-oxopiperidine-1-carboxylate (25) 
The title compound was prepared from 22 (933 mg, 4.7 mmol) following the protocol 
described for 24 above, except that stirring in the second step was carried out at 80 °C for 2 h 
(instead of 108 °C for 2 h). The crude product (yellow oil, 568 mg) was purified by flash 
column chromatography on silica gel (hexanes/EtOAc 4:1) to give the title compound as 
colorless oil (404 mg, 41%). Rf = (hexanes/EtOAc 4:1) = 0.26. Analytical data were in 
accordance with those reported previously.20 
 
4.1.7. tert-Butyl 3-methylene-2-oxoazepane-1-carboxylate (26) 
The title compound was prepared from 23 (0.30 mL, 1.4 mmol) following the protocol 
described for 24 above, except that stirring in the second step was carried out at 80 °C for 2 h 
(instead of 108 °C for 2 h). The crude product (yellow oil, 0.3674 g) was purified by flash 
column chromatography on silica gel (Hexane/EtOAc 1:1) to give the title product as 
colorless oil (301 mg, 57%). Rf = (hexanes/EtOAc 1:1) = 0.64; 1H NMR (400 MHz, CDCl3) δ 
5.77 (d, J = 1.3, 1H), 5.39 (d, J = 1.3, 1H), 3.71 – 3.64 (m, 2H), 2.47 – 2.39 (m, 2H), 1.85 – 
1.61 (m, 4H), 1.53 (s, 9H); 13C NMR (100 MHz, CDCl3): 172.6, 152.8, 147.3, 123.3, 82.7, 
46.1, 32.6, 29.2, 28.19, 28.15; HRMS (ESI): m/z [M + H]+ calcd for C12H20O3N: 226.1443; 
found: 226.1441. 
 
4.1.8. tert-Butyl 2-oxo-3-((tritylthio)methyl)pyrrolidine-1-carboxylate (27) 
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To a stirring solution of 24 (251 mg, 1.27 mmol) in dry CH2Cl2 (20 mL) was added Et3N (0.4 
mL, 2.87 mmol) and triphenylmethanethiol (705 mg, 2.55 mmol). The reaction mixture was 
stirred for 24 h at room temperature before it was washed with H2O (20 mL). The solvent was 
removed under reduced pressure to yield the crude product as yellow oil (1.26 g). Purification 
by flash column chromatography on silica gel (hexanes/EtOAc 4:1) gave the title compound 
as white foam (237 mg, 39%). Rf (hexanes/EtOAc 4:1) = 0.24; 1H NMR (400 MHz, CDCl3): δ 
= 7.44 – 7.39 (m, 6H), 7.31 – 7.25 (m, 6H), 7.23 – 7.18 (m, 3H), 3.63 (ddd, J = 11.1, 8.6, 2.3, 
1H), 3.49 – 3.41 (m, 1H), 2.78 (dd, J = 12.1, 4.0, 1H), 2.45 – 2.34 (m, 1H), 2.20 (dd, J = 12.0, 
10.4, 1H), 2.14 – 2.05 (m, 1H), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 172.9, 149.4, 
143.7, 128.7, 127.1, 125.9, 82.1, 66.0, 43.4, 42.4, 31.7, 27.2, 23.1; HRMS (ESI): m/z = 
[M+Na]+ calcd for C29H31NO3SNa: 496.1922; found: 496.1933. 
 
4.1.9. tert-Butyl 2-oxo-3-(tritylthiomethyl)piperidine-1-carboxylate (28) 
The title compound was prepared from 25 (379 mg, 1.8 mmol) following the protocol 
described for 27 above (44 h reaction time). The crude product (yellow oil, 1.52 g) was 
purified by flash column chromatography on silica gel (hexanes/EtOAc 4:1) to give the title 
compound as transparent oil (348 mg, 40%). Rf (hexanes/EtOAc 4:1) = 0.32. Analytical data 
were in accordance with those reported previously.20 
 
4.1.10. tert-Butyl 2-oxo-3-((tritylthio)methyl)azepane-1-carboxylate (29) 
The title compound was prepared from 23 (301 mg, 1.3 mmol) following the protocol 
described for 27 above (26 h reaction time). The crude product (1.03 g) was purified by flash 
column chromatography on silica gel (hexanes/EtOAc 8.5:1.5) to give the title compound as 
white foam (398 mg, 59%). Rf (hexanes/EtOAc 8.5:1.5) = 0.26; 1H NMR (400 MHz, CDCl3): 
δ = 7.51 – 7.45 (m, 6H), 7.31 – 7.24 (m, 6H), 7.22 – 7.17 (m, 3H), 4.12 – 4.03 (m, 1H), 2.96 – 
2.82 (m, 2H), 2.21 (dd, J = 13.7, 7.5, 1H), 1.80 – 1.66 (m, 3H), 1.60 – 1.52 (m, 1H), 1.49 (s, 
9H), 1.39 – 1.17 (m, 3H); 13C NMR (151 MHz, CDCl3): δ = 175.8, 153.2, 145.0, 129.8, 
128.0, 126.7, 83.0, 67.0, 46.2, 45.1, 34.2, 30.0, 28.3, 28.2, 28.1; HRMS (ESI): m/z [M + Na]+ 
calcd for C31H35NO3SNa: 524.2235; found: 524.2237.   
 
4.1.11. 4-((tert-Butoxycarbonyl)amino)-2-((tritylthio)methyl)butanoic acid (30) 
To a solution of 27 (237 mg, 0.50 mmol) in THF (10 mL) was added aqueous LiOH (1 M, 3.0 
mL, 3.0 mmol) and the resulting mixture was stirred at room temperature for 5 h. The solvent 
was removed under reduced pressure and the aqueous residue was acidified to pH 4 with 10% 
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citric acid. The mixture was extracted with CH2Cl2 (20 mL and 3 x 20 mL), washed with 
brine (30 mL), dried over MgSO4, filtered and concentrated to give the crude product (209 
mg). The crude product was purified by flash column chromatography on silica gel 
(CH2Cl2/MeOH 95:5) gave the title compound as white foam (156 mg, 64%). Rf 
(CH2Cl2/MeOH 95:5) = 0.23; 1H NMR (400 MHz, CDCl3): δ = 7.43 – 7.39 (m, 6H), 7.31 – 
7.25 (m, 6H), 7.23 – 7.18 (m, 3H), 4.56 (bs, 1H), 3.02 – 2.91 (m, 2H), 2.69 – 2.58 (m, 1H), 
2.26 – 2.18 (m, 1H), 2.07 – 1.98 (m, 1H), 1.75 – 1.49 (m, 2H), 1.42 (s, 9H); 13C NMR (100 
MHz, CDCl3): δ = 178.7, 156.4, 144.7, 129.7, 128.1, 126.9, 79.8, 67.1, 42.8, 38.3, 33.4, 32.3, 
28.5; HRMS (ESI): m/z [M + Na]+ calcd for C29H33NO4SNa: 514.2028; found: 514.2027. 
 
4.1.12. 5-(tert-Butoxycarbonylamino)-2-((tritylthio)methyl)pentanoic acid (31) 
The title compound was prepared from lactam 28 (348 mg, 0.7 mmol) following the protocol 
described for 30 above (3 h reaction time). The crude product (yellow foam, 326 mg) was 
purified by flash column chromatography on silica gel (CH2Cl2/MeOH 95:5) to give the title 
compound as yellow oil (245 mg, 68%). Rf (CH2Cl2/MeOH 95:5) = 0.30. Analytical data 
were in accordance with those reported previously.20 
 
4.1.13. 6-(tert-Butoxycarbonylamino)-2-(tritylthiomethyl)hexanoic acid (32) 
The title compound was prepared from lactam 29 (364 mg, 0.73 mmol) following the protocol 
described for 30 above, except the reaction time was 1.5 h and the pH was adjusted to ~ 3 
(instead of 4) during the aqueous work-up. The crude product (yellow oil, 369 mg) was 
purified by flash column chromatography on silica gel (CH2Cl2/MeOH 95:5) to give the title 
compound as white foam (306 mg, 81%). Rf (CH2Cl2/MeOH 95:5) = 0.31; 1H NMR (400 
MHz, CDCl3): δ = 7.43 – 7.39 (m, 6H), 7.30 – 7.24 (m, 6H), 7.22 – 7.17 (m, 3H), 4.49 (bs, 
1H), 3.05 – 2.92 (m, 2H), 2.60 (dd, J = 12.5, 8.2, 1H), 2.23 – 2.16 (m, 1H), 2.10 – 2.01 (m, 
1H), 1.43 (s, 9H), 1.40 – 1.24 (m, 4H), 1.14 – 1.02 (m, 2H); 13C NMR (150.9 MHz, CDCl3); δ 
= 179.9, 156.1, 144.7, 129.8, 128.1, 126.8, 79.3, 67.1, 45.1, 40.4, 33.1, 31.5, 29.8, 28.6, 24.2; 
HRMS (ESI): m/z [M + Na]+ calcd for C31H37NO4SNa: 542.2341; found: 542.2343.  
 
4.1.14. General protocol A: Coupling of the R2 and R3 fragments 
To a stirring solution of the secondary amine (1.40 mmol) in dry CH2Cl2 (5 mL) was added 
Fmoc-protected amino acid (1.40 mmol), HATU (545, 1.43 mmol) and DIPEA (0.75 mL, 
4.31 mmol). The reaction mixture was stirred for 23 h before the solvent was removed and the 
residue was partitioned between H2O (10 mL) and EtOAc (10 mL). The aqueous phase was 
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extracted with EtOAc (2 x 10 mL) and the combined organic phases were washed with 1 M 
KHSO4 (20 mL), H2O (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic 
phase was dried over MgSO4, filtered and concentrated to yield the crude product, which was 





The title compound was prepared from secondary amine 14 (362 mg, 1.40 mmol) and Fmoc-
Arg(Pbf)-OH (911 mg, 1.40 mmol) following general protocol A. The crude product (yellow 
foam, 1.190 g) was purified by flash column chromatography on silica gel (EtOAc/hexanes 
8:2) to give the title compound as white foam (1.060 g, 85%). Rf (EtOAc/hexanes 8:2) = 0.23; 
NMR analyses did not give useful information due to formation of rotamers; HRMS (ESI): 
m/z [M + H]+ calcd for C50H60N5O8S: 890.4163; found: 890.4163; m/z [M + Na]+ calcd for 
C50H59N5O8SNa: 912.3982; found 912.3972. 
 
4.1.16. (9H-fluoren-9-yl)methyl tert-Butyl (5-((2,2-dimethoxyethyl)(2-(naphthalen-2-
yl)ethyl)amino)-5-oxopentane-1,4-diyl)(S)-dicarbamate (34) 
The title compound was prepared from secondary amine 14 (307 mg, 1.18 mmol) and Fmoc-
Orn(Boc)-OH (539 mg, 1.19 mmol) following general protocol A. The crude product was 
purified by flash column chromatography on silica gel (EtOAc/hexane 6:4) to give the title 
compound as white foam (678 mg, 82%, retains EtOAc). Rf (EtOAc/hexane 6:4) = 0,31; 
NMR analyses did not give useful information due to formation of rotamers; HRMS (ESI): 
m/z [M + Na]+ calcd for C41H49N3O7Na: 718.3468; found: 718.3457. 
 
4.1.17. (9H-fluoren-9-yl)methyl tert-butyl (6-((2,2-dimethoxyethyl)(2-(naphthalen-2-
yl)ethyl)amino)-6-oxohexane-1,5-diyl)(S)-dicarbamate (35) 
To a stirring solution of Fmoc-Lys(Boc)-OH (551 mg, 1.2 mmol) in anhydrous DMF (2.3 
mL) was added HATU (447 mg, 1.2 mmol) and DIPEA (0.21 mL,  1.2 mmol). The reaction 
mixture was stirred for 30 min at room temperature. Secondary amine 14 (305 mg, 1.2 mmol) 
in anhydrous DMF (1.5 mL) was added and the reaction mixture was stirred for 20 h at room 
temperature. The solvent was removed and the aqueous work-up was carried out as described 
for general protocol A. The crude product (890 mg) was purified by flash column 
chromatography on silica gel (EtOAc/hexanes 8.5:1.5) to give the title compound as pale 
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yellow foam (678 mg, 71%). Rf (EtOAc/hexanes 8.5:1.5) = 0.58; NMR analyses did not give 
useful information due to formation of rotamers; HRMS (ESI): m/z [M + Na]+ calcd for 





The title compound was prepared from secondary amine 18 (847 mg, 3.45 mmol) and Fmoc-
Arg(Pbf)-OH (2.29 g, 3.53 mmol) following general protocol A (17 h reaction time). The 
crude product (yellow foam, 3.68 g) was purified by flash column chromatography on silica 
gel (EtOAc/hexanes 9:1) to give the title compound as white foam (2.110 g, 70%). Rf 
(EtOAc/hexanes 9:1) = 0.39; NMR analyses did not give useful information due to formation 





The title compound was prepared from secondary amine 19 (99 mg, 0.3 mmol) and Fmoc-
Arg(Pbf)-OH (414 mg, 0.6 mmol) following general protocol A. The crude product 
(yellowish foam, 485 mg) was purified by flash column chromatography on silica gel 
(EtOAc/hexanes, 77:23) to give the title compound as white foam (214 mg, 77%). Rf 
(EtOAc/hexanes 8:2) = 0.38; NMR analyses did not give useful information due to formation 
of rotamers; HRMS (ESI): m/z [M + H]+ calcd for C49H57O8N5BrS: 954.3111; found: 






HATU (411 mg, 1.1 mmol) and DIPEA (0.19 mL, 1.1 mmol) were added to a stirred solution 
of Fmoc-Arg(Pbf)-OH (636 mg, 1.0 mmol) in dry DMF (3 mL) under an argon atmosphere. 
The mixture was stirred for 30 minutes at room temperature before secondary amine 20 (265 
mg, 1.1 mmol) in dry DMF (2 mL) was added drop wise to the reaction mixture, and stirring 
continued for 16 hr. The reaction mixture was partitioned between H2O (10 mL) and EtOAc 
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(10 mL), and the organic phase was further washed with H2O (2 x 15 mL) and saturated 
NaCl, dried over MgSO4, filtered and concentrated to give the crude product. Purification by 
flash column chromatography (EtOAc/hexanes 4:1) gave the title compound as white foam 
(545 mg, 64%, retains EtOAc). Rf (EtOAc/hexanes 4:1) = 0.24; NMR analyses did not give 
useful information due to formation of rotamers; HRMS (ESI): m/z [M + Na]+ calcd for 
C49H57N5O8SNa: 898.3826; found: 898.3823. 
 
4.1.21. General protocol B: Fmoc-deprotection 
To a stirring solution of the Fmoc-protected amine (0.06 M in CH2Cl2) was added Et2NH (50 
equiv) and the resulting mixture was stirred at room temperature for 2-3 h (monitored by 
TLC). The solvent was removed under reduced pressure and the residue was used in the next 
step without purification. 
 
4.1.22. General protocol C: Formation of linear precursors 
To a stirring solution the carboxylic acid carrying the R1 side chain (0.31 mmol) in dry 
CH2Cl2 (2 ml) was added HATU (128 mg, 0.34 mmol) and DIPEA (0.15 ml, 0.86 mmol). The 
reaction mixture was stirred at room temperature for 40 minutes. Fmoc-deprotected amine 
(see general protocol B, 0.32 mmol) in dry CH2Cl2 (12 mL) was added and the stirring 
continued for 42 h. The solvent was evaporated to give a red residue, which was partitioned 
between H2O (10 mL) and EtOAc (10 mL). The aqueous phase was extracted with EtOAc (3 
x 10 mL) and the organic phases were combined and washed with 1 M KHSO4 (20 mL), H2O 
(20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic phase was dried over 
MgSO4, filtered and concentrated to yield the crude product, which was purified by flash 





The title compound was prepared from carboxylic acid 30 (154 mg, 0.31 mmol) and Fmoc-
deprotected amine 33 (see general protocol B, 0.32 mmol) following general protocol C. The 
crude product (red foam, 460 mg) was purified by flash column chromatography on silica gel 
(EtOAc/hexanes 8:2) to give an inseparable mixture of the two diastereoisomers of 39 (240 
mg, 67%). Rf (EtOAc/hexanes 8:2) = 0.22; NMR analyses did not give useful information due 
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to formation of rotamers; HRMS (ESI): m/z [M + H]+ calcd for C64H81N6O9S2: 1141.5506; 




The title compound was prepared from carboxylic acid 32 (267 mg, 0.51 mmol) and Fmoc-
deprotected amine 34 (see general protocol B, 0.59 mmol) following general protocol C. The 
crude product (yellow solid, 676 mg) was purified by flash column chromatography on silica 
gel (EtOAc/hexane 6:4) to give an inseparable mixture of the two diastereoisomers of 40 as 
white foam (171 mg, 34%). Rf (EtOAc/hexane 6:4) = 0.29; NMR analyses did not give useful 
information due to formation of rotamers; HRMS (ESI): m/z [M + Na]+ calcd for 





The title compound was prepared from carboxylic acid 31 (244 mg, 0.48 mmol) and Fmoc-
deprotected amine 35 (see general protocol B, 0.68 mmol) following general protocol C. The 
crude product (498 mg) was purified by flash column chromatography on silica gel 
(EtOAc/hexanes 6:4) to give an inseparable mixture of the two diastereoisomers of 41 as 
transparent oil (158 mg, 34%). Rf (EtOAc/hexanes 6:4) = 0.34; NMR analyses did not give 
useful information due to formation of rotamers; HRMS (ESI): m/z [M + Na]+ calcd for 




The title compound was prepared from carboxylic acid 30 (325 mg, 0.48 mmol) and Fmoc-
deprotected amine 35 (see general protocol B, 0.66 mmol) following general protocol C. The 
crude product (brown oil, 352 mg) was purified by flash column chromatography on silica gel 
(EtOAc/hexanes 6:4) to give to give an inseparable mixture of the two diastereoisomers of 42 
as transparent oil (205 mg, 45 %). Rf (EtOAc/hexanes 6:4) = 0.40; NMR analyses did not give 
useful information due to formation of rotamers; HRMS (ESI): m/z [M + Na]+ calcd for 






The title compound was prepared from carboxylic acid 31 (469 mg, 0.93 mmol) and Fmoc-
deprotected amine 36 (see general protocol B, 0.94 mmol) following general protocol C. The 
crude product (red foam) was purified by flash column chromatography on silica gel 
(EtOAc/hexanes 9:1) to give to give an inseparable mixture of the two diastereoisomers of 43 
as white foam (707 mg, 67%). Rf (EtOAc/hexanes 9:1) = 0.33; NMR analyses did not give 
useful information due to formation of rotamers; HRMS (ESI): m/z [M + Na]+ calcd for 





The title compound was prepared from carboxylic acid 31 (112 mg, 0.22 mmol) and Fmoc-
deprotected amine 37 (see general protocol B, 0.19 mmol) following general protocol C. The 
crude product (white foam, 384 mg) was purified by flash column chromatography on silica 
gel (EtOAc/hexanes 8.5:1.5) to give an inseparable mixture of the two diastereoisomers of 44 
as white foam (114 mg, 38 %). Rf (EtOAc/hexanes 8.5:1.5) = 0.27; NMR analyses did not 
give useful information due to formation of rotamers; HRMS (ESI): m/z [M + H]+ calcd for 





The title compound was prepared from carboxylic acid 31 (87 mg, 0.17 mmol) and Fmoc-
deprotected amine 38 (see general protocol B, 0.18 mmol) following general protocol C (18 h 
reaction time), except HBTU was used as coupling reagent. The crude product was purified 
by flash column chromatography on silica gel (EtOAc/hexanes 3:1) to give to give an 
inseparable mixture of the two diastereoisomers of 45 as white foam (0.150 mg, 75%, retains 
EtOAc). Rf (EtOAc/hexanes) = 0.24; NMR analyses did not give useful information due to 







The title compound was prepared from Boc-Cys(Trt)-OH (502 mg, 1.08 mmol) and Fmoc-
deprotected amine 36 (see general protocol B, 0.98 mmol) following general protocol C (72 h 
reaction time), except that HCTU was used as coupling reagent. The crude product (orange 
foam, 1.19 g) was purified by flash column chromatography on silica gel (EtOAc/hexanes 
9:1) to give the title compound as yellow oil (752 mg, 63%). Rf  (EtOAc/hexanes 9:1) = 0.34; 
NMR analyses did not give useful information due to formation of rotamers; HRMS (ESI): 
m/z [M + Na]+ calcd for C61H74N6O9S2Na: 1121.4856; found: 1121.4859. 
 
4.1.31. General procedure for global deprotection and cyclization 
The linear precursor was dissolved in a mixture of TFA, thioanisole and H20 (90:5:5, 100 mL 
per mmol) and the resulting mixture was stirred at room temperature for 2-4 h. The TFA was 
removed under reduced pressure and crude product was precipitated by addition of cold 
diethyl ether. The diethyl ether was removed and the residue was dried in vacuo to give the 




Linear precursor 39 (240 mg, 0.21 mmol) was deprotected and cyclized following the general 
procedure. The crude product (113 mg out of 283 mg) was dissolved in dry DMF (5 mL) and 
1H-pyrazole-1-carboxamidine hydrochloride (171 mg, 1.17 mmol) and DIPEA (0.20 mL, 
1.15 mmol) were added and the mixture was stirred under inert atmosphere for 66 h during 
which the reaction was monitored by RP-HPLC. Diethyl ether (25 mL) was then added and 
the mixture was cooled at 4 °C and stirred for an additional hour, resulting in the precipitation 
of a white solid (390 mg). The crude product was purified by semi-preparative RP-HPLC to 
give the title compound as a fluffy white solid (13.0 mg, 17%). 1H NMR (600 MHz, CD3OD): 
δ = 7.85 – 7.78 (m, 3H), 7.70 (s, 1H), 7.49 – 7.43 (m, 3H), 4.85 (m, 1H), 4.68 (HSQC, 1H), 
4.17 – 4.11 (m, 1H), 3.71 – 3.60 (m, 3H), 3.23 – 3.17 (m, 3H), 3.14 – 3.05 (m, 2H), 3.00 – 
2.94 (m, 1H), 2.91 – 2.85 (m, 1H), 2.67 – 2.55 (m, 2H), 2.05 – 1.98 (m, 1H), 1.75 – 1.68 (m, 
1H), 1.67 – 1.60 (m, 1H), 1.54 – 1.46 (m, 1H), 1.33 – 1.23 (m, 2H); 13C NMR (150.9 MHz, 
CD3OD): δ = 174.1, 170.2, 158.8, 158.5, 137.2, 135.0, 133.9, 129.3, 128.7, 128.6, 128.4, 
128.4, 127.4, 126.8, 57.3, 53.7, 48.8 (HSQC), 48.6 (HSQC), 41.4, 40.5, 40.5, 34.6, 31.2, 30.7, 
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29.8, 26.3; HRMS (ESI): m/z [M + 2H]2+ calcd for C26H38N8O2S: 263.1414; found: 263.1418. 




Bicycle 6b was prepared as described for 6a above. The crude product was purified by semi-
preparative RP-HPLC to give the title compound as a fluffy white solid (18.6 mg, 23%). 1H 
NMR (600 MHz, CD3OD): δ = 7.83 – 7.78 (m, 3H), 7.69 (s, 1H), 7.48 – 7.42 (m, 3H), 5.15 (t, 
J = 4.8, 1H), 4.87 (HSQC, 1H), 4.04 – 3.98 (m, 1H), 3.73 (dd, J = 13.9, 4.0, 1H), 3.62 – 3.56 
(m, 1H), 3.53 (dd, J = 14.0, 5.8, 1H), 3.24 – 3.20 (m, 2H), 3.11 – 3.07 (m, 2H), 3.06 – 2.97 
(m, 3H), 2.84 – 2.78 (m, 1H), 2.60 (t, J = 12.1, 1H), 2.03 – 1.95 (m, 1H), 1.70 – 1.63 (m, 3H), 
1.41 – 1.35 (m, 2H); 13C NMR (150.9 MHz, CD3OD); δ = 173.8, 169.3, 158.7, 158.5, 137.3, 
135.0, 133.8, 129.3, 128.7, 128.5, 128.5, 128.5, 127.2, 126.7, 56.6, 53.0, 50.7, 49.3 (HSQC), 
41.6, 41.4, 40.4, 34.4, 31.3, 30.1, 28.6, 26.2; HRMS (ESI): m/z [M + 2H]2+ calcd for 




Linear precursor 40 (134 mg, 0.14 mmol) was deprotected and cyclized following the general 
procedure. The crude product (134 mg) was dissolved in dry DMF (10 mL) and1H-pyrazole-
1-carboxamidine hydrochloride (165 mg, 1.13 mmol) and DIPEA (0.20 mL, 1.15 mmol) were 
added. The mixture was stirred under argon atmosphere for 66 h during which the reaction 
was monitored by RP-HPLC. Diethyl ether (25 mL) was then added and the mixture was 
cooled at 4 °C and stirred for an additional hour, resulting in the precipitation of a brown oil 
(157 mg). The crude product was purified by semi-preparative RP-HPLC to give the title 
compound as a white fluffy solid (8.5 mg, 16%). 1H NMR (600 MHz, CD3OD): δ = 7.86 – 
7.77 (m, 3H), 7.68 (s, 1H), 7.49 – 7.43 (m, 3H), 4.66 (p, J = 8.0, 2H), 4.09 – 4.03 (m, 1H), 
3.72 – 3.67 (m, 1H), 3.63 – 3.59 (m, 2H), 3.20 – 3.15 (m, 3H), 3.10 (t, J = 6.9, 2H), 3.02 – 
2.89 (m, 2H), 2.55 (t, J = 11.4, 1H), 2.40 – 2.34 (m, 1H), 1.88 – 1.79 (m, 1H), 1.66 – 1.56 (m, 
3H), 1.54 – 1.46 (m, 1H), 1.45 – 1.35 (m, 3H), 1.35 – 1.23 (m, 2H); 13C NMR (150.9 MHz, 
CD3OD); δ = 174.3, 170.4, 158.7, 158.5, 137.3, 134.9, 133.8, 129.3, 128.7, 128.7, 128.4, 
128.4, 127.3, 126.8, 57.1, 53.8, 49.0 (HSQC), 49.0 (HSQC), 43.1, 42.3, 41.5, 34.6, 31.3, 30.7, 
29.9, 29.9, 26.3, 25.4; HRMS (ESI): m/z [M + H]+ calcd for C28H41N8O2S: 553.3073; found: 





Bicycle 7b was prepared as described for 7a above. The crude product was purified by semi-
preparative RP-HPLC to give the title compound as a fluffy white solid (7.1 mg, 13%). 1H 
NMR (600 MHz, CD3OD): δ = 7.85 – 7.77 (m, 3H), 7.69 (s, 1H), 7.49 – 7.40 (m, 3H), 5.13 – 
5.09 (m, 1H), 4.88 (HSQC, 1H), 3.98 (p, J = 7.2, 1H), 3.67 (dd, J = 13.7, 4.0, 1H), 3.59 (p, J 
= 6.6, 1H), 3.52 (dd, J = 13.7, 6.2, 1H), 3.17 (t, J = 7.1, 2H) 3.11 – 3.01 (m, 5H), 2.74 – 2.68 
(m, 1H), 2.57 (t, J = 12.0, 1H), 1.93 – 1.86 (m, 1H), 1.72 – 1.64 (m, 2H), 1.64 – 1.55 (m, 2H), 
1.46 – 1.35 (m, 5H); 13C NMR (150.9 MHz, CD3OD); δ = 174.0, 169.4, 158.6, 158.5, 137.3, 
135.0, 133.8, 129.3, 128.7, 128.5, 128.5, 128.4, 127.2, 126.7, 56.6, 52.7, 51.2, 49.4 (HSQC), 
44.1, 42.3, 41.6, 34.7, 31.3, 30.1, 29.9, 28.3, 26.2, 25.1; HRMS (ESI): m/z [M + H]+ calcd for 




Linear precursor 41 (158 mg, 0.16 mmol) was deprotected and cyclized following the general 
procedure. The crude product (212 mg) was dissolved in dry DMF (10 mL) and 1H-pyrazole-
1-carboxamidine hydrochloride (132 mg, 0.90 mmol) and DIPEA (0.16 mL, 0.90 mmol) were 
added. The mixture was stirred for 72 h at room temperature during which the reaction was 
monitored by RP-HPLC. Diethyl ether (40 mL) was then added and the mixture was cooled to 
4 °C and stirred for an additional hour, resulting in the precipitation of a brown oil (163 mg). 
The crude product was purified by semi-preparative RP-HPLC to give the title compound as a 
white fluffy solid (5.5 mg, 9%). 1H NMR (600 MHz, CD3OD): δ = 7.86 – 7.76 (m, 3H), 7.69 
(s, 1H), 7.49 – 7.43 (m, 3H), 4.17 – 4.67 (m, 1H), 4.64 – 4.60 (m, 1H), 4.14 – 4.07 (m, 1H), 
3.69 – 3.62 (m, 1H), 3.62 – 3.57 (m, 2H), 3.20 – 3.15 (m, 3H), 3.12 – 3.07 (m, 2H), 2.92 (t, J 
= 7.2, 2H), 2.57 (t, J = 11.5, 1H), 2.41 (sx, J = 6.0, 1H), 1.87 – 1.80 (m, 1H), 1.68 – 1.57 (m, 
2H), 1.57 – 1.51 (m, 1H), 1.50 – 1.36 (m, 3H), 1.32 – 1.23 (m, 1H), 1.20 – 1.11 (m, 1H), 1.08 
– 1.00 (m, 1H); 13C NMR (150.9 MHz, CD3OD); δ = 173.9, 170.5, 158.6 (HMBC), 158.5 
(HMBC), 137.3, 134.9, 133.9, 129.3, 128.7 (2C), 128.5, 128.4, 127.3, 126.8, 57.7, 53.7, 48.9 
(HSQC), 48.8 (HSQC), 42.9, 42.4, 42.2, 34.6, 33.4, 29.9, 29.0, 28.8, 27.8, 24.1; HRMS (ESI): 
m/z [M + H]+ calcd for C28H41N8O2S: 553.3073; found: 553.3071,  m/z [M + 2H]2+ calcd for 





Bicycle 8b was prepared as described for 8a above. The crude product was purified by semi-
preparative RP-HPLC to give the title compound as a fluffy white solid (10 mg, 16%). 1H 
NMR (600 MHz, CD3OD): δ = 7.84 – 7.78 (m, 3H), 7.70 (s, 1H), 7.48 – 7.41 (m, 3H), 5.16 – 
5.13 (m, 1H), 4.83 (HSQC, 1H), 4.09 – 4.02 (m, 1H), 3.71 (dd, J = 14.0, 4.0, 1H), 3.57 – 3.50 
(m, 2H), 3.18 (t, J = 7.0, 2H), 3.12 – 3.04 (m, 3H), 3.00 – 2.96 (m, 2H), 2.79 – 2.72 (m, 1H), 
2.59 (t, J = 12.1, 1H), 1.93 – 1.85 (m, 1H), 1.69 – 1.54 (m, 4H), 1.50 – 1.42 (m, 2H), 1.42 – 
1.34 (m, 1H), 1.26 – 1.18 (m, 1H), 1.17 – 1.09 (m, 1H); 13C NMR (150.9 MHz, CD3OD); δ = 
173.7, 169.6, 158.7, 158.6, 137.3, 135.0, 133.8, 129.2, 128.7, 128.5, 128.5, 128.5, 127.2, 
126.6, 57.0, 53.0, 50.7, 49.2 (HSQC), 43.6, 42.4, 42.2, 34.4, 32.8, 29.1, 28.8, 28.7, 27.5, 24.0; 
HRMS (ESI): m/z [M + H]+ calcd for C28H41N8O2S: 553.3073; found: 553.3071. Purity = 




Linear precursor 42 (185 mg, 0.19 mmol) was deprotected and cyclized following the general 
procedure. The crude product (188 mg) was dissolved in dry DMF (10 mL) and 1H-pyrazole-
1-carboxamidine hydrochloride (121 mg, 0.83 mmol) and DIPEA (0.14 mL, 0.83 mmol) were 
added. The mixture was stirred for 90 h at room temperature during which the reaction was 
monitored by RP-HPLC. Diethyl ether (40 mL) was then added and the mixture was cooled to 
4 °C and stirred for an additional hour, resulting in the precipitation of a brown oil (173 mg). 
The crude product was purified by semi-preparative RP-HPLC to give the title compound as a 
white fluffy solid (4.7 mg, 6%). 1H NMR (600 MHz, CD3OD): δ = 7.86 – 7.79 (m, 3H), 7.71 
(s, 1H), 7.50 – 7.43 (m, 3H), 4.88 (dd, J = 11.0, 4.9; 1H), 4.63 (t, J = 7.9, 1H), 4.25 – 4.18 (m, 
1H), 3.69 (dd, J = 13.8, 5.1, 1H), 3.64 – 3.55 (m, 2H), 3.23 – 3.16 (m, 3H), 3.14 – 3.04 (m, 
2H), 2.92 – 2.84 (m, 2H), 2.67 – 2.56 (m, 2H), 2.04 – 1.96 (m, 1H), 1.75 – 1.68 (m, 1H), 1.56 
– 1.49 (m, 1H), 1.47 – 1.40 (m, 1H), 1.40 – 1.32 (m, 1H), 1.25 – 1.17 (m, 1H), 1.15 – 1.07 (m, 
1H), 1.02 – 0.93 (m, 1H); 13C NMR (150.9 MHz, CD3OD); δ = 173.9, 170.4, 158.8, 158.5, 
137.2, 135.0, 133.7, 129.3, 128.7, 128.7, 128.5, 128.5, 127.3, 126.7, 57.8, 53.7, 48.6 (HSQC), 
48.6 (HSQC), 42.1, 40.5, 40.5, 34.7, 33.4, 31.2, 29.9, 29.1, 24.1; HRMS (ESI): m/z [M + H]+ 
calcd for C27H39N8O2S: 539.2917; found: 539.2920, m/z [M + 2H]2+ calcd for C27H40N8O2S: 





Bicycle 9b was prepared as described for 9a above. The crude product was purified by semi-
preparative RP-HPLC to give the title compound as a fluffy white solid (5.3 mg, 7%). 1H 
NMR (600 MHz, CD3OD): δ = 7.84 – 7.77 (m, 3H), 7.69 (s, 1H), 7.48 – 7.39 (m, 3H), 5.17 
(m, 1H), 4.84 (HSQC, 1H), 4.09 – 4.02 (m, 1H), 3.73 (dd, J = 14.0, 3.8, 1H), 3.58 – 3.49 (m, 
2H), 3.24 – 3.18 (m, 2H), 3.11 – 3.07 (m, 2H), 3.04 (dd, J = 12.1, 5.6, 1H), 2.99 – 2.94 (m, 
2H), 2.83 – 2.76 (m, 1H), 2.59 (t, J = 12.1, 1H), 2.02 – 1.94 (m, 1H), 1.71 – 1.64 (m, 1H), 
1.62 – 1.55 (m, 2H), 1.50 – 1.41 (m, 1H), 1.41 – 1.33 (m, 1H), 1.26 – 1.17 (m, 1H), 1.17 – 
1.08 (m, 1H); 13C NMR (150.9 MHz, CD3OD); δ = 173.7, 169.4, 158.7, 158.5, 137.3, 135.0, 
133.8, 129.2, 128.7, 128.5, 128.5, 128.5, 127.2, 126.7, 57.1, 53.0, 50.4, 49.2 (HSQC), 42.1, 
41.2, 40.4, 34.4, 32.8, 31.2, 29.1, 28.7, 24.0; HRMS (ESI): m/z [M + H]+ calcd for 
C27H39N8O2S: 539.2917; found: 539.2919, m/z [M + 2H]2+ calcd for C27H40N8O2S: 270.1492; 




Linear precursor 45 (123 mg, 0.11 mmol) was deprotected and cyclized following the general 
procedure. The crude product (90 mg) was dissolved in DMF (10 mL) and 1H-pyrazole-1-
carboxamidine hydrochloride (103 mg, 0.70 mmol) and DIPEA (0.1 mL, 0.57 mmol) were 
added. The mixture was stirred under argon atmosphere for 69 h during which the reaction 
was monitored by RP-HPLC. Diethyl ether (30 mL) was then added and the mixture was 
cooled at 4 °C and stirred for an additional hour, resulting in the precipitation of a brown solid 
(118 mg). The crude product was purified by semi-preparative RP-HPLC to give the title 
compound as inseparable diastereoisomers as fluffy white solid  (25.5 mg, 31%). 1H NMR 
(500 MHz, CD3OD): δ = 7.90 – 7.78 (m, 8H), 7.54 – 7.46 (m, 4H), 7.42 (dd, J = 8.5, 1.7, 2H), 
5.25 – 5.21 (m, 2H), 5.16 (dd, J = 10.9, 5.6, 1H), 5.10 (dd, J = 9.2, 6.0, 1H), 4.89 (HSQC), 
4.77 (d, J = 14.6, 1H), 4.67 (d, J = 14.6, 1H), 3.81 – 3.63 (m, 4H), 3.26 (HSQC), 3.19 (q, J = 
7.5, 4H), 3.05 (dd, J = 11.7, 5.1, 1H), 2.84 – 2.69 (m, 3H), 2.64 (t, J = 11.4, 1H), 2.04 – 1.85 
(m, 6H), 1.77 – 1.59 (m, 8H), 1.59 – 1.45 (m, 2H); 13C NMR (150.9 MHz, CD3OD); δ = 
174.5, 173.9, 170.8, 169.7, 158.7, 158.6, 134.87, 134.85, 134,80, 134.6, 134.5 (2C), 130.0, 
129.8, 128.84, 128.82, 128.74, 128.72, 128.6, 128.5, 127.6, 127.5, 127.4, 127.3, 127.1, 126.8, 
57.3, 56.8, 54.1, 52.9, 51.2, 50.9, 50.0, 47.7, 43.8, 42.9, 42.2, 42.38, 41.8, 41.7, 31.0, 30.3, 
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30.0, 28.9, 28.8, 28.4, 27.7, 27.4, 26.7, 26.5; HRMS (ESI): m/z [M + H]+ calcd for 




Linear precursor 44 (112 mg, 0.1 mmol) was deprotected and cyclized following the general 
procedure. The crude product (31 mg out of 33 mg) was dissolved in dry DMF (3 mL) and 
1H-pyrazole-1-carboxamidine hydrochloride (32 mg, 0.2 mmol) and DIPEA (0.2 mL, 1.2 
mmol) were added and stirring continued for 72 h (monitored by RP-HPLC) under inert 
atmosphere at room temperature. Diethyl ether (25 mL) was added to the mixture and stirring 
continued up to one additional hour on ice/water bath. The crude product precipitated as a 
white solid. The solvent was removed to give the crude product as a white sticky material (31 
mg). The crude product was purified by semi-preparative RP-HPLC to give the title 
compounds as a yellowish fluffy powder (6 mg, 8 %). 1H NMR (600 MHz, CD3OD): δ = 
8.35-8.31 (m, 2H), 7.94-7.88 (m, 4H), 7.69-7.63 (m, 2H), 7.62-7.57 (m, 2H), 7.46-7.42 (m, 
2H), 5.27-5.21 (m, 2H), 5.14-5.08 (m, 2H), 5.08, 5.01 (ABq, JAB = 15.2, 2H), 4.95-4.90 (m, 
3H), 3.82-3.76 (m, 2H), 3.69 (dd, J = 13.8, 5.3, 1H), 3.65 (dd, J = 13.8, 6.4, 1H), 3.29-3.25 
(m, 4H), 3.22-3.17 (m, 4H), 3.04 (dd, J = 11.8, 5.0, 1H), 2.87-2.78 (m, 2H), 2.78-2.71 (m, 
1H), 2.66 (app t, J = 11.4, 1H), 2.07-1.98 (m, 1H), 1.98-1.90 (m, 5H), 1.78-1.60 (m, 8H), 
1.60-1.46 (m, 2H); 13C NMR (150.9 MHz, CD3OD); δ = 174.5, 173.9, 170.8, 169.8, 158.66, 
158.65, 158.63, 135.6 (2C), 134.5, 134.3, 133.63, 133.60, 127.7, 129.6, 129.43, 129.41, 
129.1, 129.0, 128.2, 128.14, 128.11, 128.1, 127.8, 127.6, 124.8, 124.6, 57.3, 56.9, 54.1, 52.8, 
51.9, 51.8, 50.5, 48.1,  43.9, 42.9,  42.42, 42.38, 41.8, 41.7, 31.0, 30.3, 30.1, 28.93, 28.85, 
28.4, 27.7, 27.4, 26.7, 26.5; HRMS (ESI): m/z [M + H]+ calcd for C26H3679BrN8O2S: 
603.1865; found: 603.1862; m/z [M + H]+ calcd for C26H3681BrN8O2S: 605.1845; found: 




The linear precursor 43 (1.556 g, 1.58 mmol) was deprotected and cyclized following the 
general procedure. The crude product (718 mg out of 989 mg) was guanidinylated following 
the procedure described for 6a to give the crude product as yellow foam (821 mg). A small 
sample was purified by semi-preparative RP-HPLC to give the title compounds as a fluffy 
white solid. 1H NMR (600 MHz, CD3OD): δ = 8.12-8.07 (m, 2H), 7.96-7.87 (m, 4H), 7.56-
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7.45 (m, 8H), 5.32-5.24 (m, 2H), 5.15 (dd, J = 6.2, 4.1, 1H), 5.11 (dd, J = 9.0, 6.1, 1H), 5.06-
5.01 (m, 2H), 4.97-4.89 (m, 2H), 3.64 (dd, J = 13.8, 5.3, 1H), 3.57 (dd, J = 13.9, 4.2, 1H), 
3.50 (dd, J = 13.9, 6.3, 1H), 3.45 (dd, J = 13.8, 11.4, 1H), 3.26-3.21 (m, 5H), 3.20-3.14 (m, 
4H), 3.00 (dd, J = 12.2, 5.5, 1H), 2.79-2.70 (m, 2H), 2.67-2.58 (m, 2H), 2.01-1.81 (m, 6H), 
1.76-1.42 (m, 9H), 1.40-1.35 (m, 1H); 13C NMR (150.9 MHz, CD3OD); δ = 174.4, 173.9, 
170.2, 169.2, 158.63, 158.59, 135.56, 135.53, 133.0, 132.8, 132.5, 132.3, 130.4, 130.3, 130.1, 
130.0, 129.3, 129.2, 127.7, 127.6, 127.3, 127.2, 126.5, 126.3, 124.7, 124.6, 57.4, 56.9, 54.0, 
52.9, 49.2 (HSQC), 49.0 (HSQC), 48.8 (HSQC), 48.5 (HSQC), 48.3, 46.7, 43.8, 42.9, 42.43, 
42.38, 41.77, 41.72, 30.9, 30.2, 30.0, 28.89, 28.82, 28.4, 27.7, 27.4, 26.7, 26.5; HRMS (ESI): 
m/z [M + H]+ calcd for C26H37N8O2S: 525.2760; found: 525.2765. Purity = 97.0% (sum of 




The linear precursor 43 (132 mg, 0.12 mmol) was cyclized following the general procedure to 
give 71 mg of crude product. Purification by semi-preparative RP-HPLC gave the title 
compounds as a fluffy white solid (18.9 mg, 30%). 1H NMR (600 MHz, CD3OD): δ = 7.89-
7.83 (m, 6H), 7.81 (d, J = 9.1, 2H), 7.53-7.47 (m, 4H), 7.42 (d, J = 8.3, 2H), 5.25-5.22 (m, 
1H), 5.17 (dd, J = 10.9, 5.3, 1H), 5.09 (dd, J = 8.1, 6.6, 1H), 4.93-4.87 (m, 3H), 4.77 (d, J = 
14.4, 1H), 4.67 (d, J = 14.6, 1H), 3.82-3.63 (m, 4H), 3.30-3.22 (m, 5H), 3.05 (dd, J = 12.0, 
5.1, 1H), 2.97-2.91 (m, 4H), 2.85-2.79 (m, 2H), 2.73 (t, J = 11.9, 1H), 2.65 (t, J = 11.5, 1H), 
2.04-1.87 (m, 6H), 1.83-1.67 (m, 8H), 1.60-1.48 (m, 2H); 13C NMR (150.9 MHz, CD3OD); δ 
= 174.6, 174.1, 171.0, 169.9, 158.96, 158.92, 135.2, 135.14, 135.09, 134.9, 134.80, 134.79, 
130.3, 130.1, 129.15, 129.13, 129.03, 129.01, 128.9, 128.8, 127.9, 127.8,  127.7, 127.6, 127.5, 
127.1, 57.6, 57.1, 54.4, 53.3, 51.5, 51.2, 50.3, 48.0, 43.9, 43.1, 42.1, 42.0, 40.9, 40.8, 31.3, 
30.7, 30.3, 28.9, 28.8, 28.7, 27.0, 26.78, 26.77, 26.4;  HRMS (ESI): m/z [M + H]+ calcd for 




Linear precursor 46 (74 mg, 0.91 mmol) was cyclized following the general procedure to give 
80 mg of crude product. Purification by semi-preparative RP-HPLC gave the title compound 
as a fluffy white solid (1.62 mg, 4%). 1H NMR (600 MHz, CD3OD): δ = 8.23 (d, J = 8.6, 1H), 
7.84 (d, J = 7.9, 1H), 7.82 (d, J = 8.6, 1H), 7.61-7.57 (m, 1H), 7.52-7.48 (m, 1H), 7.26 (d, J = 
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8.5, 1H), 5.24 (d, J = 18.3, 1H), 4.98 (dd, J = 7.8, 5.4, 1H), 4.86 (overlap with residual water, 
1H), 4.42 (d, J = 18.3, 1H), 3.95 (dd, J = 14.7, 1.7, 1H), 3.76 (dd, J = 12.1, 4.2, 1H), 3.70 (dd, 
J = 14.7, 1.7, 1H), 3.54 (dd, J = 14.3, 4.2, 1H), 3.31 (overlap with solvent peak, 1H), 3.18 (dd, 
J = 14.3, 12.1, 1H), 2.11-2.06 (m, 1H), 1.82-1.71 (m, 3H); 13C NMR (150.9 MHz, CD3OD); δ 
= 172.1, 169.3, 158.6, 134.1, 132.2, 132.0, 130.3, 129.6, 128.7, 127.8, 127.0, 125.3, 124.5, 
55.4, 50.7, 48.1, 46.8, 46.2, 42.2, 37.8, 29.4, 26.1; HRMS (ESI): m/z [M + H]+ calcd for 
C22H29N6O2S: 441.2073; found: 441.2070. 
 
4.2. Biology - COS-7 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with Glutamax (1% glutamine), supplemented with 10% FBS, 180U/ml 
penicillin and 45µg/ml streptomycin in a 10% CO2/90% humidified atmosphere. The cells 
were transfected by the calcium phosphate precipitation method, where plasmid DNA (10 µg 
of receptor cDNA and 15 µg of the chimeric Gαi signal-converting G protein Gαδ6qi4myr) was 
mixed with TE buffer (10 mM Tris-HCl, 2 mM Na2EDTA, pH 7.5) and 30 µl CaCl2 (2 M). 
This mixture was added to 240 µl HEPES buffered saline (280 mM NaCl, 50 mM HEPES, 
1.5 mM Na2HPO4, pH 7.2). The mixture was allowed to stand for 45 minutes at room 
temperature for precipitation. Together with 150 µl chloroquine (2 mg/ml), it was thereafter 
added to 5 ml culture media to the 6 × 106 COS-7 cells seeded the day before. The 
transfection was stopped after 5 hours by replacing the culture media, and the cells were 
incubated overnight. 
 
The scintillation proximity-based inositol-phosphate accumulation assay (SPA-IP) was used 
to measure the potency of the potential antagonists. One day after transfection, the COS-7 
cells were seeded in wells (35,000 cells/well) and were incubated for 24 hours with Myo-[2-
3H(N)]-inositol (5 µl/ml) in 100 µl of culture media per well in 96-well plate. The subsequent 
day, the cells were washed twice in Hank’s balanced salt solution (HBSS, Invitrogen, U.K.) 
and incubated for 90 minutes in HBSS supplemented with 10 mM LiCl at 37 °C in the 
presence of the potential antagonists and CXCL12. Amounts of CXCL12 added induced up to 
80% of full receptor activation. Cell lysis was induced by addition of 40 µl formic acid (10 
mM) to each well, followed by incubation on ice for 30 minutes. For quantification of 
[3H]inositol-phosphates in the formic acid cell lysates, 80 µl of a Ysi-poly-D-Lys coated SPA 
bead suspension (12.5 µg/µl in H2O, PerkinElmer) were added to 35 µl cell lysates in a Pico-
Plate-96 white plate. The plates were sealed, agitated for 30 minutes and centrifuged (5 
minutes, 1500 rpm). The SPA beads were allowed to settle and react with the extract for 8 
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hours before the radioactivity was measured in a Packard Top Count NXTTM scintillation 
counter (PerkinElmer, MA, USA). All determinations were made in duplicate.  
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